CJC-1295 with vs without DAC is one of the most consequential distinctions in growth hormone secretagogue research, because a single chemical modification — the Drug Affinity Complex (DAC) — transforms an otherwise short-acting GHRH analog into a long-circulating one. Both formats are synthetic analogs of growth hormone-releasing hormone (GHRH), and both are used strictly as reference compounds in laboratory and in-vitro investigation. What separates them is not the receptor they engage but how long they persist in circulation and, consequently, the shape of the growth hormone signal they generate in research models. This article contrasts those two kinetic profiles at the mechanistic level.
Research Use Only. All compounds discussed here are intended exclusively for laboratory, in-vitro, and preclinical research use. They are not for human or veterinary use, are not dietary supplements, and have not been evaluated by the FDA. Nothing here is intended to diagnose, treat, cure, or prevent any disease, and no human dosing guidance is provided.
The Shared Backbone: Modified GRF(1-29)
Both "with DAC" and "without DAC" versions are built on the same peptide scaffold: a modified fragment of GHRH known as GRF(1-29), the 29-amino-acid N-terminal segment that retains the full biological activity of the 44-residue native hormone. Native GHRH is notoriously fragile — the enzyme dipeptidyl peptidase-4 (DPP-4) cleaves it at the Ala²–Asp³ bond within minutes, giving native GHRH a plasma half-life measured in seconds to a couple of minutes. To stabilize the molecule, researchers introduced four amino-acid substitutions (commonly summarized as D-Ala², Gln⁸, Ala¹⁵, Leu²⁷). These substitutions resist enzymatic degradation and reduce aggregation, producing the compound frequently called modified GRF(1-29), CJC-1295 without DAC, or sometimes simply "Mod GRF."
This is the critical point of confusion the comparison resolves: the substitutions alone do not create a long-acting peptide. They extend half-life from seconds to roughly 30 minutes in reported models — meaningful, but still short. The dramatic half-life extension comes only from the DAC add-on. For the underlying receptor biology shared by both, see our GHRH & Growth Hormone Axis mechanism guide.
What DAC Actually Does
The Drug Affinity Complex is a maleimidopropionic acid (MPA) linker attached to the peptide. When introduced into a biological medium containing serum albumin, this reactive group forms a covalent bond with a cysteine residue (Cys34) on circulating albumin. Because albumin is one of the most abundant plasma proteins and has a very long circulating half-life of its own (~19 days in humans), tethering the GHRH analog to albumin shields it from renal clearance and enzymatic breakdown. The result reported in the literature is a plasma half-life extended to roughly 6–8 days for the DAC-conjugated format.
Mechanistically, the peptide's receptor-binding N-terminus remains free to engage the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs while the albumin "anchor" acts as a slow-release depot. This is why the with-DAC compound is described as producing a "GH bleed" or sustained elevation, whereas the no-DAC compound produces discrete pulses. To understand why half-life reshapes signaling this profoundly, our peptide half-life and kinetics primer covers the pharmacokinetic principles.
Side-by-Side: Kinetic and Signaling Profiles
| Attribute | CJC-1295 WITHOUT DAC (Mod GRF 1-29) | CJC-1295 WITH DAC |
|---|---|---|
| Core structure | Modified GRF(1-29), 4 substitutions | Modified GRF(1-29) + MPA/DAC linker |
| Albumin binding | None | Covalent, via Cys34 |
| Reported plasma half-life | ~30 minutes | ~6–8 days |
| GH signal shape | Sharp, pulsatile spike | Sustained, tonic elevation ("GH bleed") |
| Relationship to natural pulsatility | Preserves discrete pulses | Flattens the pulse pattern |
| Frequency in study designs | Higher administration frequency modeled | Lower frequency; long exposure window |
| Common research pairing | Ghrelin mimetics (e.g., Ipamorelin) | Often studied standalone |
Pulsatile vs Tonic Signaling — Why It Matters in Models
Endogenous growth hormone is released in pulses, and downstream receptor biology is sensitive to that rhythm. Research on GH signaling has shown that pulsatile versus continuous exposure can activate different transcriptional programs — for instance, sexually dimorphic hepatic gene expression in rodent models is governed by GH pulse pattern rather than total GH quantity. The no-DAC format, with its rapid clearance, is therefore favored in research designs that aim to mimic physiological pulsatility. The with-DAC format, by holding GHRH-R engagement elevated for days, is a tool for studying sustained secretagogue drive and the feedback consequences of a flattened pulse profile, including negative feedback via somatostatin and IGF-1.
Why the No-DAC Format Is Frequently Paired With Ipamorelin
A recurring theme in secretagogue research is the combination of a GHRH analog with a ghrelin receptor (GHS-R1a) agonist. GHRH analogs and ghrelin mimetics act on two distinct receptors and two distinct intracellular pathways — cAMP/PKA for GHRH-R and phospholipase C/IP₃/calcium for GHS-R1a — producing a synergistic, greater-than-additive GH release when studied together. The short-acting no-DAC format is the natural partner here because its sharp kinetics align with the equally short, pulse-shaped release from a ghrelin mimetic such as Ipamorelin, keeping both signals synchronized within the same brief window. This is the rationale behind the popular blended reference preparation. For a deeper treatment of that specific pairing, see the CJC-1295 no DAC + Ipamorelin blend research guide. The DAC format, being tonic rather than pulsatile, is less commonly co-formulated this way and is more often examined on its own, as covered in the CJC-1295 with DAC research guide.
Laboratory Handling Considerations
Both formats are supplied as lyophilized powders and share broadly similar handling requirements for research preparations:
- Reconstitution: bacteriostatic or sterile water is typically used to solubilize the lyophilized peptide for in-vitro work; the solvent is directed down the vial wall rather than onto the peptide cake to limit shear.
- Storage of lyophilized material: stored desiccated and cold (commonly −20 °C or below) protects the reference standard for long-term stability.
- Reconstituted solution: generally kept refrigerated (2–8 °C) and protected from light; the DAC format's albumin-binding chemistry does not change basic solution-handling practice, though care with freeze-thaw cycles applies to both.
- Purity verification: a third-party Certificate of Analysis (COA) confirming ≥99% purity by HPLC and identity by mass spectrometry is essential for reproducible data, since the DAC linker and the four substitutions must be present exactly as specified.
Choosing a Reference Compound for a Study Design
The selection between formats is fundamentally a question of the kinetic hypothesis being tested. A protocol investigating physiological pulse mimicry, receptor desensitization dynamics over short intervals, or GHRH/ghrelin synergy points toward the no-DAC format. A protocol examining sustained GHRH-R drive, prolonged exposure effects, or negative-feedback adaptation over days points toward the with-DAC format. Neither is "stronger" in the abstract — they generate categorically different signal shapes from the same receptor.
Featured Research Reference Compounds
- CJC-1295 with DAC 5mg — the albumin-binding, long-half-life GHRH analog for tonic-signaling research models.
- CJC-1295 (no DAC) + Ipamorelin 5+5mg blend — the short-acting, pulse-synchronized GHRH-analog and ghrelin-mimetic combination.
Both are third-party COA-tested to ≥99% purity, shipped same-day from the USA, for laboratory research use only. For the broader research context, return to our pillar overview of Growth Hormone Secretagogue Peptides.